Genmab - ADR Forecast, price target & analysts
Genmab - ADR Target price 2025 - Analyst rating & recommendation
Genmab - ADR Classifications & Recommendation:
Genmab - ADR Price Target
| Target Price | $31.05 |
| Price | $20.63 |
| Potential |
50.50%
register free of charge
|
| Number of Estimates | 20 |
|
20 Analysts have issued a price target Genmab - ADR 2026 .
The average Genmab - ADR target price is $31.05.
This is
50.50%
register free of charge
$45.00
118.13%
register free of charge
$14.62
29.16%
register free of charge
|
|
| A rating was issued by 27 analysts: 18 Analysts recommend Genmab - ADR to buy, 8 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Genmab - ADR stock has an average upside potential 2026 of
50.50%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 3.12 | 3.64 |
| 30.60% | 16.47% | |
| EBITDA Margin | 34.45% | 35.11% |
| 0.49% | 1.91% | |
| Net Margin | 36.03% | 26.20% |
| 39.72% | 27.28% |
24 Analysts have issued a sales forecast Genmab - ADR 2025 . The average Genmab - ADR sales estimate is
This results in the following potential growth metrics:
23 Genmab - ADR Analysts have issued a net profit forecast 2025. The average Genmab - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.77 | 1.50 |
| 82.47% | 15.25% | |
| P/E | 13.76 | |
| EV/Sales | 2.72 |
23 Analysts have issued a Genmab - ADR forecast for earnings per share. The average Genmab - ADR EPS is
This results in the following potential growth metrics and future valuations:
Current Genmab - ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HSBC |
Locked
➜
Locked
|
Locked | Mar 23 2025 |
| REDBURN ATLANTIC |
Locked
➜
Locked
|
Locked | Mar 21 2025 |
| TRUIST SECURITIES |
Locked
➜
Locked
|
Locked | Mar 16 2025 |
| NYKREDIT MARKETS |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| DNB MARKETS |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
| GUGGENHEIM SECURITIES LLC |
Locked
➜
Locked
|
Locked | Mar 09 2025 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Mar 09 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HSBC:
Locked
➜
Locked
|
Mar 23 2025 |
|
Locked
REDBURN ATLANTIC:
Locked
➜
Locked
|
Mar 21 2025 |
|
Locked
TRUIST SECURITIES:
Locked
➜
Locked
|
Mar 16 2025 |
|
Locked
NYKREDIT MARKETS:
Locked
➜
Locked
|
Mar 13 2025 |
|
Locked
DNB MARKETS:
Locked
➜
Locked
|
Mar 10 2025 |
|
Locked
GUGGENHEIM SECURITIES LLC:
Locked
➜
Locked
|
Mar 09 2025 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Mar 09 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
